

4th World congress on Diabetes and Endocrine Disorders

Dr. Omo Ojo

Senior Lecturer University of Greenwich London, United Kingdom.

Corresponding author:

Dr. Omo Ojo


Senior Lecturer University of Greenwich London, United Kingdom, E-mail: O.Ojo@greenwich.ac.uk

Copyright: © 2020 Ojo O, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Global [diabetes market](#) is expected to grow at a CAGR of 7.6% percent for the forecasted period of 2018-2023. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest [growth rate](#) with a CAGR of 8.9%. Some of the top selling diabetic drugs include Lantus (Sanofi), Januvia (Merck And Co), Humalog (Eli Lilly And Co), Novorapid (Novo Nordisk), Levemir (Novo Nordisk), Victoza (Novo Nordisk), Janumet (Merck And Co.), Novolog (Novo Nordisk), Humalin (Eli Lilly And Co.) And Galvus (Novartis). With the diabetic population expected to cross the 350 million market by 2030 the market is expected to show strong growth rate. [Diabetic drugs](#) are highly priced which could be one of the major drawbacks.

could be one of the major drawbacks.



Moreover, the aging population within the U.S.A. has been on the increase since the 1960's. individuals aged sixty five years and on top of accounted for around 11th of September of the overall population in 1960 whereas in 2018, this cohort accounted for around 15 August 1945 of the whole U.S.A. population. Driven by rising incidences of polygenic disorder and therefore the incontrovertible fact that the U.S.A. has one amongst the very best per capita tending expenditures, the U.S.A. marketplace for polygenic disorder medication has grown up at a CAGR of around eleven.8% throughout 2011-2018, reaching a price of US\$ forty five.4 Billion in 2018.

Diabetes has increasingly become a lifestyle related disease as it afflicts young and old. As the number of patients grow across the globe, there has never been a stronger and more urgent need for novel therapeutic measures in clinical and preclinical evaluation, that arrest the growth of the disease. The diabetes market, consisting mainly of Type 1 and Type 2 diabetes is large and growing significantly. Global diabetes market is expected to grow at CAGR of 7.6% for the forecasted period of 2018-2023.the market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 8.9% . some of the top selling diabetic drugs include Lantus(sanofi), Januvia(Merck and Co), Humalog(Eli Lilly And Co),Novo rapid(Novo Nordisk),Levemir(NovoNordisk),Victoza(NovoNordisk),Janumet(Merck And Co),Novolog(Novo Nordisk),Humalin (Eli Lilly And

Co) and Galvus (Novartis).with the diabetic population expected to cross the 350 million market by 2030 the market is expected to show strong growth rate. Diabetic drugs are highly priced which

Diabetes drug research market in Europe is expected to progress with a 5.08% CAGR over the forecast years of 2018-2026. It is the second largest market for diabetes drugs. High blood glucose kills about 3.4 million people annually worldwide. Approximately 80% of these deaths take place in underdeveloped and developing countries, and almost half are people aged less than 70 years. As per recent research in WHO diabetic deaths will double between 2005 and 2030. India had 69.2 million people living with diabetes (8.7%) in 2015. About 90% of the patients are suffering from Type 2 diabetes. Diabetes Research Market is expected to grow at the average CAGR of 6.5% time period of 2016-2023. India's Diabetes Market is growing rapidly. India is expected to grow US\$ 7441.6 million by 2023 from US\$ 4778.7 million in 2016. The data varies from \$263 billion spent in North America to \$147 billion in Europe and Northern Asia. Followed by China, Mongolia, South East Asia and Oceania with a total of \$88 billion.

Societies Associated with Diabetes Research:

- SBDR - Society for Biomedical Diabetes Research
- Austrian Diabetes Association
- Flemish Diabetes Association
- Association of Juvenile Diabetes
- Canadian Diabetes Association
- Juvenile Diabetes Foundation of Chile
- German Diabetes Union

- Diabetic Society of Singapore
- Japan Diabetes Society
- Hong Kong Diabetes Federation
- The International Society of Gynecological Endocrinology
- Royal Society of Medicine Endocrinology and Diabetes Section
- International Society of Psych neuroendocrinology
- International Neuroendocrine Federation
- European Society of Endocrinology
- Clinical Endocrinology Trust
- Swiss Diabetes Society
- Spanish Diabetes Society
- Korean Diabetes Association

- Canadian Diabetes Association in Sydney
- Major Diabetes Research Associations around Globe
- International Diabetes Federation
 - American Diabetes Association
 - Canadian Diabetes Association
 - Diabetes New Zealand
 - Diabetes United Kingdom
 - Glycosmedia
 - Diabetes Indian Association
 - Diabetes Australia
 - Austrian Diabetes Association
 - Diabetes UK
 - Diabetes South Africa
 - Spanish Diabetes Society (Spain)
 - Swedish Diabetes Association
 - Korean Diabetes Association

Major Diabetes Research Associations around Asia Pacific

- Diabetes Australia Research Program
- Juvenile Diabetes Research Foundation (JDRF)
- The Australian Centre for Behavioural Research in Diabetes
- The Diabetes Research Foundation Western Australia
- The John Curtin School of Medical Research
- The NHMRC Centre of Clinical Research Excellence on Clinical Science in Diabetes (Diabetes CCRE)
- Baker
- The Walter and Eliza Hall Institute of Medical Research
- Diabetes Australia
- Austrian Diabetes Association
- Dietitians Association of Australia
- Diabetes Association Brisbane

Major Universities on Diabetes Research

- Albany Medical College
- Baylor College of Medicine
- Creighton University School of Medicine
- Dartmouth Medical School
- Florida International University College of Medicine
- Georgetown University School of Medicine
- Howard University College of Medicine
- Harvard Medical School
- Johns Hopkins University School of Medicine

World diabetes cases expected to jump 55% by 2035

